Trial Profile
A Prospective, Observational, Non-Interventional, Post-Marketing, Patient Registry to Collect Data on Routine Clinical Care in Patients Treated With Cholbam® (Cholic Acid)
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 Oct 2023
Price :
$35
*
At a glance
- Drugs Cholic acid (Primary)
- Indications Inborn genetic disorders; Infantile Refsum disease; Peroxisomal disorders; Zellweger syndrome
- Focus Adverse reactions
- Acronyms REPLACE Registry
- Sponsors Mirum Pharmaceuticals; Travere Therapeutics
- 06 Feb 2023 Status changed from recruiting to active, no longer recruiting.
- 07 Dec 2020 Planned number of patients changed from 110 to 55.
- 29 Jun 2020 Planned End Date changed from 1 Aug 2030 to 1 Jul 2039.